Description

MAHACEF-CV 200 MG (1X6)

Indications

MAHACEF-CV 200 MG is a combination antibiotic medication primarily indicated for the treatment of various bacterial infections. It is commonly used to manage respiratory tract infections, urinary tract infections, skin and soft tissue infections, and certain types of gastrointestinal infections. The formulation combines cefixime, a cephalosporin antibiotic, with clavulanic acid, which helps to inhibit beta-lactamase enzymes produced by resistant bacteria, thereby enhancing the efficacy of cefixime against a broader spectrum of pathogens.

Mechanism of Action

The active ingredient, cefixime, exerts its antibacterial effect by inhibiting bacterial cell wall synthesis. It binds to penicillin-binding proteins (PBPs) located within the bacterial cell wall, disrupting the cross-linking of peptidoglycan layers, which is crucial for maintaining cell wall integrity. This leads to cell lysis and ultimately the death of the bacteria. Clavulanic acid, on the other hand, acts as a beta-lactamase inhibitor. By binding to and inactivating these enzymes, it prevents the breakdown of cefixime, allowing it to remain effective against beta-lactamase-producing strains of bacteria.

Pharmacological Properties

MAHACEF-CV 200 MG is characterized by its pharmacokinetic properties that allow for effective treatment of infections. Cefixime is well-absorbed from the gastrointestinal tract, with peak plasma concentrations occurring approximately 2-6 hours after oral administration. It has a half-life of about 3-4 hours, allowing for once or twice daily dosing. The drug is primarily excreted unchanged in the urine. Clavulanic acid has a shorter half-life but is also excreted renally. The combination of these two agents provides a synergistic effect, enhancing the overall antibacterial activity of the formulation.

Contraindications

MAHACEF-CV 200 MG is contraindicated in patients with a known hypersensitivity to cefixime, clavulanic acid, or any other cephalosporin antibiotics. It should also be avoided in individuals with a history of severe allergic reactions to penicillins, as cross-reactivity may occur. Patients with a history of liver dysfunction or jaundice related to previous use of clavulanic acid should not use this medication. Additionally, caution is advised in patients with renal impairment, as dosage adjustments may be necessary.

Side Effects

Common side effects associated with MAHACEF-CV 200 MG include gastrointestinal disturbances such as diarrhea, nausea, vomiting, and abdominal pain. Other reported side effects may include rash, itching, and allergic reactions. In rare cases, more serious adverse effects such as liver enzyme elevation, jaundice, and severe allergic reactions (anaphylaxis) may occur. It is important for patients to report any unusual symptoms to their healthcare provider promptly. Monitoring for side effects is crucial, especially in patients with pre-existing conditions.

Dosage and Administration

The recommended dosage of MAHACEF-CV 200 MG varies depending on the type and severity of the infection being treated. For adults and children over 12 years of age, the typical dose is one tablet taken orally every 12 hours or as directed by a healthcare professional. For children aged 6 to 12 years, the dosage is usually based on body weight and should be determined by a physician. It is essential to complete the full course of therapy as prescribed, even if symptoms improve before finishing the medication, to prevent the development of antibiotic resistance.

Interactions

MAHACEF-CV 200 MG may interact with other medications, which can affect its efficacy or increase the risk of adverse effects. Notably, concurrent use with probenecid can increase cefixime levels in the blood, potentially leading to toxicity. Anticoagulants such as warfarin may have altered effects when taken with MAHACEF-CV, necessitating close monitoring of coagulation parameters. Additionally, the use of other antibiotics should be approached with caution, as it may lead to reduced effectiveness or increased side effects. Patients should inform their healthcare provider of all medications they are currently taking to avoid potential interactions.

Precautions

Before initiating treatment with MAHACEF-CV 200 MG, a thorough medical history should be taken to assess for any previous allergic reactions to antibiotics, particularly cephalosporins and penicillins. It is important to monitor renal function during treatment, especially in patients with pre-existing kidney conditions. Patients should also be advised to maintain adequate hydration to support renal clearance of the medication. Pregnant and breastfeeding women should consult their healthcare provider before using this medication, as safety during pregnancy and lactation has not been fully established.

Clinical Studies

Clinical studies evaluating the efficacy and safety of MAHACEF-CV 200 MG have demonstrated its effectiveness in treating various bacterial infections. In one study, patients with uncomplicated urinary tract infections showed significant improvement after a course of treatment with this combination antibiotic, with a high rate of bacterial eradication. Another study focused on respiratory tract infections indicated that MAHACEF-CV was well-tolerated and effective in reducing symptoms and bacterial load. These studies support the use of MAHACEF-CV 200 MG as a valuable option in the management of bacterial infections, particularly those caused by resistant strains.

Conclusion

MAHACEF-CV 200 MG is a potent combination antibiotic that offers a broad spectrum of activity against various bacterial infections. Its unique formulation of cefixime and clavulanic acid enhances its effectiveness, particularly against beta-lactamase-producing bacteria. While generally well-tolerated, it is essential for patients to be aware of potential side effects and interactions with other medications. Proper usage, adherence to prescribed dosages, and communication with healthcare providers are crucial to ensuring successful treatment outcomes and minimizing the risk of antibiotic resistance.